-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Inetagugene Geperpavec in Harlequin Ichthyosis (Autosomal Recessive Congenital Ichthyosis 4B)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inetagugene Geperpavec in Harlequin Ichthyosis (Autosomal Recessive Congenital Ichthyosis 4B) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Inetagugene Geperpavec in Harlequin Ichthyosis (Autosomal Recessive...
-
Company Profile
Krystal Biotech Inc – Company Profile
Krystal Biotech Inc (Krystal Biotech) is a gene therapy company that develops and commercializes treatments for dermatological diseases. The company’s pipeline includes B-VEC (bercolagene telserpavec) gene therapy, against dystrophic epidermolysis bullosa (DEB), KB105 therapy, targeting autosomal recessive congenital ichthyosis (ARCI), a genetic skin disease caused due to deficiency of TGM1 gene. Krystal Biotech also investigating KB301, to treat aesthetic skin conditions, KB104, against Netherton Syndrome, KB407, for the treatment of Junctional Epidermolysis Bullosa (JEB) and KB5XX, targeting chronic skin diseases....
Add to Basket -
Product Insights
Arcis Solar PV Park
Each power plant profile includes core details such as plant name, technology, capacity, status, plant proponents (owners, developers etc.), owner stakes etc as well as key operational data including generation, year online, decommissioning year, capital expenditure etc. Details on project specific contacts along with relevant news, deals and contracts are also provided through the plant profile. This is an on-demand report that will be delivered upon request. The report will be delivered within 1 business day of the purchase, excluding...
-
Product Insights
Net Present Value Model: Inetagugene Geperpavec
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Inetagugene Geperpavec Drug Details KB-105 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – inetagugene geperpavec
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry inetagugene geperpavec Drug Details KB-105 is under development for the treatment of TGM-1-deficient autosomal...
-
Sector Analysis
United Kingdom In Vitro Diagnostics Market Outlook to 2025 – Cardiac Disease, Clinical Chemistry, Hematological Disorders and Others.
GlobalData’s “United Kingdom In Vitro Diagnostics Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United Kingdom In Vitro Diagnostics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Cardiac Disease, Clinical Chemistry, Hematological Disorders, Hormonal Disorders, Infectious Disease, IVD Analyzers and Reagents, Metabolic Disorder, Oncology and Women's Health. The United Kingdom In Vitro Diagnostics Market report provides key information and data on: • Annualized market...
-
Sector Analysis
Spain In Vitro Diagnostics Market Outlook to 2025 – Cardiac Disease, Clinical Chemistry, Hematological Disorders and Others.
GlobalData’s “Spain In Vitro Diagnostics Market Outlook to 2025” is a comprehensive databook report, covering key market data on the Spain In Vitro Diagnostics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Cardiac Disease, Clinical Chemistry, Hematological Disorders, Hormonal Disorders, Infectious Disease, IVD Analyzers and Reagents, Metabolic Disorder, Oncology and Women's Health. The Spain In Vitro Diagnostics Market report provides key information and data on: • Annualized market revenues (USD), volume...